85 related articles for article (PubMed ID: 19925616)
1. Internal validation of an artificial neural network for prostate biopsy outcome.
Stephan C; Cammann H; Bender M; Miller K; Lein M; Jung K; Meyer HA
Int J Urol; 2010 Jan; 17(1):62-8. PubMed ID: 19925616
[TBL] [Abstract][Full Text] [Related]
2. An artificial neural network for five different assay systems of prostate-specific antigen in prostate cancer diagnostics.
Stephan C; Cammann H; Meyer HA; Müller C; Deger S; Lein M; Jung K
BJU Int; 2008 Sep; 102(7):799-805. PubMed ID: 18522632
[TBL] [Abstract][Full Text] [Related]
3. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network.
Stephan C; Cammann H; Deger S; Schrader M; Meyer HA; Miller K; Lein M; Jung K
Urology; 2009 Oct; 74(4):873-7. PubMed ID: 19476981
[TBL] [Abstract][Full Text] [Related]
4. A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases.
Stephan C; Kahrs AM; Cammann H; Lein M; Schrader M; Deger S; Miller K; Jung K
Prostate; 2009 Feb; 69(2):198-207. PubMed ID: 18942119
[TBL] [Abstract][Full Text] [Related]
5. A (-5, -7) proPSA based artificial neural network to detect prostate cancer.
Stephan C; Meyer HA; Kwiatkowski M; Recker F; Cammann H; Loening SA; Jung K; Lein M
Eur Urol; 2006 Nov; 50(5):1014-20. PubMed ID: 16697520
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection.
Stephan C; Jung K; Soosaipillai A; Yousef GM; Cammann H; Meyer H; Xu C; Diamandis EP
BJU Int; 2005 Sep; 96(4):521-7. PubMed ID: 16104903
[TBL] [Abstract][Full Text] [Related]
7. Outcome prediction for prostate cancer detection rate with artificial neural network (ANN) in daily routine.
Ecke TH; Bartel P; Hallmann S; Koch S; Ruttloff J; Cammann H; Lein M; Schrader M; Miller K; Stephan C
Urol Oncol; 2012; 30(2):139-44. PubMed ID: 20363164
[TBL] [Abstract][Full Text] [Related]
8. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
9. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW
J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
[TBL] [Abstract][Full Text] [Related]
10. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
Stephan C; Stroebel G; Heinau M; Lenz A; Roemer A; Lein M; Schnorr D; Loening SA; Jung K
Cancer; 2005 Sep; 104(5):993-1003. PubMed ID: 16007682
[TBL] [Abstract][Full Text] [Related]
11. Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA.
Parsons JK; Brawer MK; Cheli CD; Partin AW; Djavan R
BJU Int; 2004 Jul; 94(1):47-50. PubMed ID: 15217429
[TBL] [Abstract][Full Text] [Related]
12. Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics.
Jung K; Hoesel W; Reiche J; Deger S; Kramer J; Loening SA; Lein M; Stephan C
Urology; 2007 Feb; 69(2):320-5. PubMed ID: 17320672
[TBL] [Abstract][Full Text] [Related]
13. Neuro-fuzzy system for prostate cancer diagnosis.
Benecchi L
Urology; 2006 Aug; 68(2):357-61. PubMed ID: 16904452
[TBL] [Abstract][Full Text] [Related]
14. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Brux B; Sinha P; Schnorr D; Loening SA
Anticancer Res; 2000; 20(6D):4997-5001. PubMed ID: 11326657
[TBL] [Abstract][Full Text] [Related]
15. An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml. or less.
Zlotta AR; Remzi M; Snow PB; Schulman CC; Marberger M; Djavan B
J Urol; 2003 May; 169(5):1724-8. PubMed ID: 12686818
[TBL] [Abstract][Full Text] [Related]
16. Comparison of two different artificial neural networks for prostate biopsy indication in two different patient populations.
Stephan C; Xu C; Finne P; Cammann H; Meyer HA; Lein M; Jung K; Stenman UH
Urology; 2007 Sep; 70(3):596-601. PubMed ID: 17688922
[TBL] [Abstract][Full Text] [Related]
17. Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies.
Stephan C; Kramer J; Meyer HA; Kristiansen G; Ziemer S; Deger S; Lein M; Loening SA; Jung K
BJU Int; 2007 Jun; 99(6):1427-31. PubMed ID: 17355366
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of various prostate specific antigen ratios for the early detection of prostate cancer.
Ozdal OL; Aprikian AG; Bégin LR; Behlouli H; Tanguay S
BJU Int; 2004 May; 93(7):970-4; discussion 974. PubMed ID: 15142145
[TBL] [Abstract][Full Text] [Related]
19. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
Partin AW; Brawer MK; Bartsch G; Horninger W; Taneja SS; Lepor H; Babaian R; Childs SJ; Stamey T; Fritsche HA; Sokoll L; Chan DW; Thiel RP; Cheli CD
J Urol; 2003 Nov; 170(5):1787-91. PubMed ID: 14532777
[TBL] [Abstract][Full Text] [Related]
20. Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy.
Kawakami S; Numao N; Okubo Y; Koga F; Yamamoto S; Saito K; Fujii Y; Yonese J; Masuda H; Kihara K; Fukui I
Eur Urol; 2008 Sep; 54(3):601-11. PubMed ID: 18207312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
